Glutamate and Neurodegeneration in the Retina
Publisher
Springer New York
Reference83 articles.
1. Allergan Inc. (2008). Press release on Memantine Trials, Fourth Quarter Operating Results, Jan 30 2008. Press Release,
http://agn.client.shareholder.com/releasedetail.cfm?ReleaseID=290764 2. Almasieh, M., Wilson, A. M., Morquette, B., Cueva Vargas, J. L., & Di Polo, A. (2012). The molecular basis of retinal ganglion cell death in glaucoma. Progress in Retinal and Eye Research, 31, 152–181. 3. Baltmr, A., Duggan, J., Nizari, S., Salt, T. E., & Cordeiro, M. F. (2010). Neuroprotection in glaucoma – Is there a future role? Experimental Eye Research, 91, 554–566. 4. Battaglia, G., Molinaro, G., Riozzi, B., Storto, M., Busceti, C. L., Spinsanti, P., Bucci, D., Di Liberto, V., Mudo, G., Corti, C., Corsi, M., Nicoletti, F., Belluardo, N., & Bruno, V. (2009). Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons. PloS One, 4, e6591. 5. Beart, P. M., & O’Shea, R. D. (2007). Transporters for L-glutamate: An update on their molecular pharmacology and pathological involvement. British Journal of Pharmacology, 150, 5–17.
|
|